Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.
Italiano
A
A
Delcambre
C
C
Hostein
I
I
Cazeau
A L
AL
Marty
M
M
Avril
A
A
Coindre
J-M
JM
Bui
B
B
D005260:Female; D006338:Heart Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D054973:Perivascular Epithelioid Cell Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
D047908:Intracellular Signaling Peptides and Proteins; D047428:Protein Kinase Inhibitors; C401859:temsirolimus; C546842:MTOR protein, human; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus